1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Ayala Launches First Biopharma IPO In May

 
• By Mandy Jackson

The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m. 

Finance Watch

Ayala Pharmaceuticals Inc. and Lyra Therapeutics Inc. said in US Securities and Exchange Commission (SEC) paperwork filed on the same day that they were gearing up to launch initial public offerings, but the two companies went public a week apart, grossing $55m and $64m, respectively.

Rehovot, Israel- and Wilmington, DE-based Ayala sold 3.67m shares at $15 each on 7 May, pricing the offering in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By Kevin Grogan

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.